AMS Biotechnology (AMSBIO) has TIGIT receptor products for immunotherapy research. Human T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibition motif (ITIM) domains—TIGIT—is a receptor expressed on the surface of human T cells and natural killer cells that binds to CD155 and CD112 present on the surface of dendritic cells. Antibodies and other agents that inhibit this signaling pathway increase the immune response, particularly in certain cancers. A recombinant Jurkat cell line that constitutively expresses a full-length human TIGIT and a firefly luciferase gene under the control of nuclear factor of activated T-cell (NFAT) response elements is available to identify antagonistic monoclonal antibodies. Two TIGIT homogeneous assay kits measure the inhibition of TIGIT binding to CD112 (PVRL2/Nectin-2) and CD155, respectively. AMSBIO has also launched Fc Fusion TIGIT and biotinylated Fc Fusion TIGIT recombinant proteins for protein-binding studies and for screening small molecules and antibodies.